Amicus Therapeutics, Inc.(NASDAQ : FOLD)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.45%||166.93||0.7%||$1253.55m|
|LLY||Eli Lilly & Co.||0.18%||311.43||1.1%||$814.08m|
|BMY||Bristol-Myers Squibb Co.||-0.73%||70.77||1.0%||$778.85m|
|MRK||Merck & Co., Inc.||-0.81%||86.80||0.7%||$691.58m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-0.95%||200.78||8.2%||$207.03m|
|GBT||Global Blood Therapeutics, Inc.||0.03%||67.99||5.4%||$199.71m|
|NVO||Novo Nordisk A/S||-0.40%||97.92||0.1%||$170.11m|
|HZNP||Horizon Therapeutics Plc||0.54%||62.97||5.4%||$156.21m|
|SRPT||Sarepta Therapeutics, Inc.||-2.42%||108.19||12.4%||$128.76m|
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.